Drotrecogin alfa (activated): real-life use and outcomes for the UK
about
Study protocol: the Back Pain Outcomes using Longitudinal Data (BOLD) registry.Methods for estimating subgroup effects in cost-effectiveness analyses that use observational data.The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approachIs Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated).Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomesGrowing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.Protein C and acute inflammation: a clinical and biological perspective.Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.Drotrecogin alfa (activated): a single-centre experience of 110 patients.Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes.Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.
P2860
Q34254913-A0C40DF2-DF67-4E1E-832E-CF61FE2A5C25Q34301425-D74FCBBE-6C15-471C-8587-BB71277378BAQ34981434-84527F65-90F6-47F1-969E-294699F6E571Q35908186-20A1137A-7668-4352-8E42-82A57B864133Q36112774-5B21E67F-2693-4C83-8F02-4B12F15F9915Q36919457-E116B926-1C86-492D-8B48-1B21A605169FQ37279933-2E0BAE76-BE63-4AB3-B599-814613AB8353Q37354434-861BA6CE-A665-4768-A5F4-79285366E6A6Q38126264-08890625-611E-4421-9216-5CB88EA22BD7Q39370623-D71CCCD6-9982-422A-98B9-2EE92BFC9830Q42412734-6348080C-E3DD-4684-9E0A-7D4C0FFA7542Q46283807-540B30A7-96FA-4815-B9DE-437C3271F1D5Q48006853-235C88BF-3DA2-4966-8D8D-17AC8104A6E3Q48221454-7CAFD626-306E-40B0-B3C3-664406D7B1DDQ49505268-434AF438-7DBD-47D2-9ECC-439BC484462A
P2860
Drotrecogin alfa (activated): real-life use and outcomes for the UK
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Drotrecogin alfa (activated): real-life use and outcomes for the UK
@en
type
label
Drotrecogin alfa (activated): real-life use and outcomes for the UK
@en
prefLabel
Drotrecogin alfa (activated): real-life use and outcomes for the UK
@en
P2860
P356
P1433
P1476
Drotrecogin alfa (activated): real-life use and outcomes for the UK
@en
P2093
Emma North
Kathryn M Rowan
P2860
P2888
P356
10.1186/CC6879
P577
2008-04-22T00:00:00Z
P5875
P6179
1041248135